# Skinspire Clinic
## Financial Performance Analysis 2025
### Executive Presentation

---

## SLIDE 1: Title Slide

**SKINSPIRE CLINIC**
**Financial Performance Analysis**
**Period: January - December 2025**

Prepared for: CEO & Management Team
Date: January 2025
Confidential

---

## SLIDE 2: About Skinspire Clinic

### Clinic Overview

**Skinspire Clinic** is a modern healthcare facility specializing in comprehensive dermatology and aesthetic medicine services.

**Key Information:**
- **Established**: Multi-specialty dermatology clinic
- **Services**: Skin care, aesthetic treatments, dermatology consultations
- **Operations**: Multiple revenue streams (consultations, procedures, pharmacy)
- **Financial Year**: January to December
- **Average Medicine Inventory**: â‚¹10,00,000

**Infrastructure:**
- Modern healthcare management system
- Digital payment capabilities
- Integrated pharmacy operations
- Patient-centric care delivery

---

## SLIDE 3: Executive Summary Dashboard

### 10-Month Performance Overview (Jan-Oct 2025)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    KEY FINANCIAL METRICS                        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                 â”‚
â”‚  TOTAL REVENUE          â”‚  â‚¹93,95,272  â”‚  100.00%             â”‚
â”‚  Operating Expenses     â”‚  â‚¹46,83,720  â”‚   49.85%             â”‚
â”‚  GROSS PROFIT          â”‚  â‚¹47,11,552  â”‚   50.15%             â”‚
â”‚                                                                 â”‚
â”‚  Other Expenses:                                               â”‚
â”‚  - Capital Expenditure  â”‚  â‚¹10,79,391  â”‚   11.49%             â”‚
â”‚  - Personal Expenses    â”‚   â‚¹9,61,573  â”‚   10.23%             â”‚
â”‚  - Loan Interest        â”‚   â‚¹2,38,365  â”‚    2.54%             â”‚
â”‚                                                                 â”‚
â”‚  NET PROFIT            â”‚  â‚¹24,32,223  â”‚   25.89%             â”‚
â”‚                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Performance Rating: B+ (Strong Foundation, Needs Stabilization)**

âœ… **Strengths**: 50% Gross Margin, Positive Cash Flow, Diversified Revenue
âš ï¸ **Concerns**: Revenue Volatility, 3 Loss-Making Months, High CapEx

---

## SLIDE 4: Revenue Analysis - Total â‚¹93.95 Lakhs

### Revenue Mix (10 Months: Jan-Oct 2025)

**BY COLLECTION METHOD:**

| Source | Amount (â‚¹) | % Share | Monthly Avg |
|--------|------------|---------|-------------|
| **Bank Collections** | 71,48,083 | 76.1% | 7,14,808 |
| **Cash Collections** | 22,47,189 | 23.9% | 2,24,719 |
| **TOTAL** | **93,95,272** | **100.0%** | **9,39,527** |

**GRAPH DATA (Monthly Revenue Trend):**
```
Month     | Bank (â‚¹)  | Cash (â‚¹)  | Total (â‚¹)  | Growth %
----------|-----------|-----------|------------|----------
Jan-25    | 8,42,207  | 2,68,408  | 11,10,615  | Baseline
Feb-25    | 5,10,172  | 1,19,608  |  6,29,780  | -43.3%
Mar-25    | 7,85,014  | 1,77,567  |  9,62,581  | +52.8%
Apr-25    | 6,30,454  | 1,52,994  |  7,83,448  | -18.6%
May-25    | 7,09,660  | 1,45,544  |  8,55,204  | +9.2%
Jun-25    | 8,58,367  | 1,07,089  |  9,65,456  | +12.9%
Jul-25    | 9,08,188  | 4,39,356  | 13,47,544  | +39.6% â­
Aug-25    | 9,08,174  | 3,34,920  | 12,43,094  | -7.7%
Sep-25    | 4,96,069  | 3,00,036  |  7,96,105  | -36.0% âš ï¸
Oct-25    | 4,99,778  | 2,01,667  |  7,01,445  | -11.9%
```

**Key Insights:**
- ğŸ”´ High volatility: â‚¹6.3L to â‚¹13.5L range (114% variance)
- â­ Peak: July (â‚¹13.5L) - 39.6% jump
- ğŸ”´ Trough: February (â‚¹6.3L) - 43% decline
- ğŸ“‰ Q3 Decline: 25% drop from July peak

---

## SLIDE 5: Monthly Revenue Trend (GRAPH)

### Visual: Revenue Trend Chart

```
Revenue (â‚¹ Lakhs)
    14â”‚                    â­
      â”‚                   â•± â•²
    12â”‚                  â•±   â•²
      â”‚                 â•±     â•²
    10â”‚      â•±â•²  â•±â”€â•²  â•±        â•²
      â”‚     â•±  â•²â•±   â•²â•±          â•²
     8â”‚    â•±                     â•²
      â”‚   â•±                       â•²  â•²
     6â”‚  â•±âš ï¸                        â•²  â•²
      â”‚                                â•²
     4â”‚
      â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
       J F M A M J J A S O N D
       2025 â†’

Legend:
â”â”â” Total Revenue
â­ Peak Month (July: â‚¹13.5L)
âš ï¸ Low Month (Feb: â‚¹6.3L)
```

**Trend Analysis:**
- **Q1 (Jan-Mar)**: Volatile start (â‚¹6.3L to â‚¹11.1L)
- **Q2 (Apr-Jun)**: Stabilizing (â‚¹7.8L to â‚¹9.7L)
- **Q3 (Jul-Sep)**: Peak & crash (â‚¹13.5L to â‚¹8.0L)
- **Q4 Projection**: Recovery expected (â‚¹8-9L)

---

## SLIDE 6: Operating Expense Analysis

### Clinic Operating Expenses: â‚¹46.84 Lakhs (49.85% of Revenue)

**MONTHLY OPERATING EXPENSE RATIO:**

| Month | Revenue (â‚¹) | OpEx (â‚¹) | OpEx % | Efficiency |
|-------|------------|----------|--------|------------|
| Jan-25 | 11,10,615 | 5,46,768 | 49.2% | âœ… Good |
| Feb-25 | 6,29,780 | 4,40,076 | 69.9% | ğŸ”´ High |
| Mar-25 | 9,62,581 | 5,33,648 | 55.4% | ğŸŸ¡ Fair |
| Apr-25 | 7,83,448 | 3,26,278 | 41.7% | âœ… Excellent |
| May-25 | 8,55,204 | 4,55,958 | 53.3% | âœ… Good |
| Jun-25 | 9,65,456 | 5,02,990 | 52.1% | âœ… Good |
| Jul-25 | 13,47,544 | 2,70,102 | 20.1% | âœ…âœ… Exceptional |
| Aug-25 | 12,43,094 | 4,89,903 | 39.4% | âœ… Excellent |
| Sep-25 | 7,96,105 | 6,93,200 | 87.1% | ğŸ”´ğŸ”´ Critical |
| Oct-25 | 7,01,445 | 4,24,798 | 60.6% | ğŸŸ¡ Fair |

**GRAPH DATA (OpEx % Trend):**
```
OpEx %
  90â”‚              âš ï¸
  80â”‚             â•±
  70â”‚   âš ï¸       â•±
  60â”‚      â•²           â•²
  50â”‚ â”€â”€â”€â”€â”€â•²â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•²â”€â”€â”€â”€â”€ Target (50%)
  40â”‚       â•²â”€â•²   â­
  30â”‚          â•² â•±
  20â”‚           â­
  10â”‚
    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
     J F M A M J J A S O
```

**Critical Findings:**
- ğŸ”´ **September Crisis**: 87% OpEx ratio (â‚¹6.93L on â‚¹7.96L revenue)
- â­ **Best Months**: July (20%), August (39%), April (42%)
- ğŸ¯ **Target**: <45% of revenue (currently 49.85%)
- ğŸ’° **Savings Potential**: â‚¹4.7L annually if target achieved

---

## SLIDE 7: Profitability Analysis

### Monthly Profit Performance

| Month | Revenue (â‚¹) | Gross Profit (â‚¹) | GP% | Net Profit (â‚¹) | NP% | Status |
|-------|------------|-----------------|-----|----------------|-----|--------|
| Jan-25 | 11,10,615 | 5,63,847 | 50.8% | 3,85,901 | 34.8% | âœ… |
| Feb-25 | 6,29,780 | 1,89,704 | 30.1% | -2,01,319 | -32.0% | ğŸ”´ Loss |
| Mar-25 | 9,62,581 | 4,28,933 | 44.6% | 2,53,142 | 26.3% | âœ… |
| Apr-25 | 7,83,448 | 4,57,170 | 58.4% | 2,70,615 | 34.5% | âœ… |
| May-25 | 8,55,204 | 3,99,246 | 46.7% | -29,086 | -0.3% | ğŸ”´ Loss |
| Jun-25 | 9,65,456 | 4,62,466 | 47.9% | 1,95,833 | 20.3% | âœ… |
| Jul-25 | 13,47,544 | 10,77,442 | 80.0% | 9,08,366 | 67.4% | â­â­ Best |
| Aug-25 | 12,43,094 | 7,53,191 | 60.6% | 6,04,753 | 48.7% | â­ |
| Sep-25 | 7,96,105 | 1,02,905 | 12.9% | -40,448 | -5.1% | ğŸ”´ Loss |
| Oct-25 | 7,01,445 | 2,76,647 | 39.4% | 84,466 | 12.0% | ğŸŸ¡ |

**PROFITABILITY SUMMARY:**

```
âœ… PROFITABLE MONTHS: 7/10 (70%)
ğŸ”´ LOSS-MAKING MONTHS: 3/10 (30%)

ğŸ† TOP PERFORMERS:
  1. July    : â‚¹9.08L profit (67.4% margin)
  2. August  : â‚¹6.05L profit (48.7% margin)
  3. January : â‚¹3.86L profit (34.8% margin)

âš ï¸ LOSS MONTHS:
  1. February : -â‚¹2.01L (Low revenue + High expenses)
  2. September: -â‚¹0.40L (Expense crisis)
  3. May      : -â‚¹0.29L (High CapEx)

TOTAL NET PROFIT (10 months): â‚¹24,32,223 (25.89% margin)
```

---

## SLIDE 8: Net Profit Trend (GRAPH)

### Visual: Monthly Net Profit Performance

```
Net Profit (â‚¹ Lakhs)
    10â”‚                   â­
      â”‚                  â•± â•²
     8â”‚                 â•±   â•²
      â”‚                â•±     â­
     6â”‚               â•±       â•²
      â”‚              â•±
     4â”‚  â•±â•²     â•±â•²  â•±          â•²
      â”‚ â•±  â•²   â•±  â•²â•±
     2â”‚â•±    â•² â•±                 â•²â”€
      â”‚      â•²â•±
     0â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
      â”‚    âš ï¸  âš ï¸           âš ï¸
    -2â”‚   â•±
      â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
       J F M A M J J A S O

Legend:
â”â”â” Net Profit
â­ Profitable months
âš ï¸ Loss months
```

**Profit Distribution:**
- **Cumulative Profit**: â‚¹26.75L (profitable months)
- **Cumulative Loss**: -â‚¹2.71L (loss months)
- **Net Position**: â‚¹24.32L
- **Average Monthly Profit**: â‚¹2.43L

---

## SLIDE 9: Capital Expenditure Breakdown

### Total CapEx: â‚¹13.18 Lakhs (14% of Revenue)

**MONTHLY CAPITAL EXPENDITURE:**

| Month | Cash CapEx (â‚¹) | Regular CapEx (â‚¹) | Loan Interest (â‚¹) | Total (â‚¹) |
|-------|---------------|------------------|------------------|-----------|
| Jan-25 | - | 15,035 | 25,464 | 40,499 |
| Feb-25 | 1,70,000 | 1,61,516 | 23,158 | 1,84,674 |
| Mar-25 | 2,50,000 | 1,31,276 | 22,997 | 1,54,273 |
| Apr-25 | 2,50,000 | 1,22,581 | 22,607 | 1,45,188 |
| May-25 | 30,000 | 3,51,946 | 23,690 | 3,75,636 |
| Jun-25 | - | 1,19,037 | 22,280 | 1,41,317 |
| Jul-25 | 69,000 | 50,000 | 38,612 | 88,612 |
| Aug-25 | - | 80,000 | 21,979 | 1,01,979 |
| Sep-25 | - | 48,000 | 18,662 | 66,662 |
| Oct-25 | - | - | 18,916 | 18,916 |
| **TOTAL** | **7,69,000** | **10,79,391** | **2,38,365** | **13,17,756** |

**CAPEX ANALYSIS:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  Major Investment Periods:               â”‚
â”‚  â€¢ Feb-Apr: â‚¹6.7L (Equipment purchase)   â”‚
â”‚  â€¢ May: â‚¹3.5L (Peak investment month)    â”‚
â”‚  â€¢ Jul-Oct: Minimal CapEx                â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

Investment Pattern:
  High Investment (Feb-May): â‚¹10.4L (79%)
  Low Investment (Jun-Oct): â‚¹2.8L (21%)
```

**Impact on Profitability:**
- CapEx consumed 27.97% of gross profit
- High CapEx months correlated with lower net profit
- No additional CapEx assumed for Nov-Dec

---

## SLIDE 10: Cash Flow Analysis

### Bank vs Cash Performance (10 Months)

**CASH FLOW SUMMARY:**

| Metric | Bank (â‚¹) | Cash (â‚¹) | Total (â‚¹) | % Share |
|--------|----------|----------|-----------|---------|
| **Collections** | 71,48,083 | 22,47,189 | 93,95,272 | 100.0% |
| **Expenditure** | 62,94,049 | 7,69,000 | 70,63,049 | 75.2% |
| **Net Cash Flow** | 9,54,034 | 14,78,189 | 24,32,223 | 25.9% |
| **Share of Profit** | 39.2% | 60.8% | 100.0% | - |

**MONTHLY CASH FLOW PATTERN:**

| Month | Bank Net (â‚¹) | Cash Net (â‚¹) | Combined | Status |
|-------|-------------|-------------|----------|--------|
| Jan-25 | 1,17,493 | 2,68,408 | 3,85,901 | âœ…âœ… Both Strong |
| Feb-25 | -1,50,927 | -50,392 | -2,01,319 | ğŸ”´ğŸ”´ Both Negative |
| Mar-25 | 3,25,575 | -72,433 | 2,53,142 | ğŸŸ¡ Bank Strong |
| Apr-25 | 3,67,621 | -97,006 | 2,70,615 | ğŸŸ¡ Bank Strong |
| May-25 | -1,44,630 | 1,15,544 | -29,086 | ğŸŸ¡ Cash Strong |
| Jun-25 | 88,744 | 1,07,089 | 1,95,833 | âœ… Both Positive |
| Jul-25 | 5,38,010 | 3,70,356 | 9,08,366 | â­â­ Exceptional |
| Aug-25 | 2,69,833 | 3,34,920 | 6,04,753 | âœ… Both Strong |
| Sep-25 | -3,40,484 | 3,00,036 | -40,448 | ğŸ”´ Bank Critical |
| Oct-25 | -1,17,201 | 2,01,667 | 84,466 | ğŸŸ¡ Cash Strong |

**KEY OBSERVATIONS:**
- ğŸ’š Cash Flow: Positive in 7/10 months (70% resilience)
- ğŸ”´ Bank Flow: Negative in 4/10 months (40% volatility)
- âš ï¸ September Bank: -â‚¹3.4L (largest single month loss)
- ğŸ’ª Cash Strength: 55% higher contribution than bank

---

## SLIDE 11: Nov-Dec 2025 Projections

### Revenue & Expense Projections (Based on Q3-Q4 Trend)

**PROJECTION METHODOLOGY:**
- **Revenue**: Conservative estimate based on Sep-Oct average with seasonal recovery
- **Operating Expenses**: 50% ratio (current 10-month average: 49.85%)
- **Capital Expenditure**: Zero (as per assumption)
- **Personal Expenses**: 10% of revenue (historical average)
- **Loan Interest**: â‚¹19,000/month (recent trend)

**NOVEMBER 2025 PROJECTION:**

| Item | Amount (â‚¹) | % of Revenue |
|------|-----------|--------------|
| **Revenue (Bank + Cash)** | 8,50,000 | 100.0% |
| â€¢ Bank Collections | 6,40,000 | 75.3% |
| â€¢ Cash Collections | 2,10,000 | 24.7% |
| **Operating Expenses** | 4,25,000 | 50.0% |
| **Gross Profit** | 4,25,000 | 50.0% |
| **Other Expenses** | | |
| â€¢ Personal Expenses | 85,000 | 10.0% |
| â€¢ Loan Interest | 19,000 | 2.2% |
| **Net Profit** | 3,21,000 | 37.8% |

**DECEMBER 2025 PROJECTION:**

| Item | Amount (â‚¹) | % of Revenue |
|------|-----------|--------------|
| **Revenue (Bank + Cash)** | 9,00,000 | 100.0% |
| â€¢ Bank Collections | 6,75,000 | 75.0% |
| â€¢ Cash Collections | 2,25,000 | 25.0% |
| **Operating Expenses** | 4,50,000 | 50.0% |
| **Gross Profit** | 4,50,000 | 50.0% |
| **Other Expenses** | | |
| â€¢ Personal Expenses | 90,000 | 10.0% |
| â€¢ Loan Interest | 19,000 | 2.1% |
| **Net Profit** | 3,41,000 | 37.9% |

**PROJECTION CONFIDENCE:**
- **Moderate (70%)** - Based on historical Q4 recovery pattern
- **Assumptions**: No major expense anomalies, normal operations
- **Risks**: Continued Q3 decline trend, unexpected expenses

---

## SLIDE 12: Full Year 2025 Projections

### Projected Annual Performance (Jan-Dec 2025)

**12-MONTH PROJECTED SUMMARY:**

| Metric | Jan-Oct (Actual) | Nov-Dec (Projected) | Full Year 2025 | % of Revenue |
|--------|-----------------|---------------------|----------------|--------------|
| **Total Revenue** | 93,95,272 | 17,50,000 | **1,11,45,272** | 100.0% |
| â€¢ Bank Collections | 71,48,083 | 13,15,000 | 84,63,083 | 75.9% |
| â€¢ Cash Collections | 22,47,189 | 4,35,000 | 26,82,189 | 24.1% |
| | | | | |
| **Operating Expenses** | 46,83,720 | 8,75,000 | **55,58,720** | 49.9% |
| **Gross Profit** | 47,11,552 | 8,75,000 | **55,86,552** | 50.1% |
| | | | | |
| **Other Expenses:** | | | | |
| â€¢ Capital Expenditure | 10,79,391 | - | 10,79,391 | 9.7% |
| â€¢ Personal Expenses | 9,61,573 | 1,75,000 | 11,36,573 | 10.2% |
| â€¢ Loan Interest | 2,38,365 | 38,000 | 2,76,365 | 2.5% |
| **Total Other Expenses** | 22,79,329 | 2,13,000 | **24,92,329** | 22.4% |
| | | | | |
| **NET PROFIT** | 24,32,223 | 6,62,000 | **30,94,223** | **27.8%** |

**FULL YEAR INSIGHTS:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  PROJECTED ANNUAL PERFORMANCE (2025)                      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚  Revenue          : â‚¹1.11 Crores (Monthly Avg: â‚¹9.29L)   â”‚
â”‚  Gross Profit     : 50.1% (Healthy margin)                â”‚
â”‚  Net Profit       : 27.8% (Strong bottom line)            â”‚
â”‚  Total Profit     : â‚¹30.94 Lakhs                          â”‚
â”‚                                                           â”‚
â”‚  Profitability Status: 9 Profitable / 3 Loss Months      â”‚
â”‚  Cash Flow Status: Positive (â‚¹30.94L generated)          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## SLIDE 13: Profit & Loss Statement (Jan-Dec 2025)

### Comprehensive P&L Statement

```
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
                    SKINSPIRE CLINIC
           PROFIT & LOSS STATEMENT (PROJECTED)
         For the Period: January 1 - December 31, 2025
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

INCOME                                           Amount (â‚¹)    %
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Bank Collections                                 84,63,083   75.9%
Cash Collections                                 26,82,189   24.1%
                                              â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”€â”€â”€â”€â”€
TOTAL INCOME                                   1,11,45,272  100.0%


COST OF OPERATIONS
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Clinic Operating Expenses                        55,58,720   49.9%
                                              â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”€â”€â”€â”€â”€
GROSS PROFIT                                     55,86,552   50.1%


OTHER EXPENSES
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Capital Expenditure                              10,79,391    9.7%
Personal Expenses                                11,36,573   10.2%
Loan Interest                                     2,76,365    2.5%
                                              â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”€â”€â”€â”€â”€
TOTAL OTHER EXPENSES                             24,92,329   22.4%


PROFIT BEFORE TAX                                30,94,223   27.8%
Less: Income Tax Provision (Estimated)                   -    0.0%
                                              â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”€â”€â”€â”€â”€
NET PROFIT AFTER TAX                             30,94,223   27.8%


â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
                         SUMMARY RATIOS
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Gross Profit Margin                                           50.1%
Operating Expense Ratio                                       49.9%
Net Profit Margin                                             27.8%
Return on Revenue                                             27.8%
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•


MONTHLY BREAKDOWN (â‚¹):

Month      Income      OpEx      Gross Profit   Net Profit   NP%
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Jan-25   11,10,615   5,46,768     5,63,847      3,85,901   34.8%
Feb-25    6,29,780   4,40,076     1,89,704     -2,01,319  -32.0%
Mar-25    9,62,581   5,33,648     4,28,933      2,53,142   26.3%
Apr-25    7,83,448   3,26,278     4,57,170      2,70,615   34.5%
May-25    8,55,204   4,55,958     3,99,246        -29,086   -0.3%
Jun-25    9,65,456   5,02,990     4,62,466      1,95,833   20.3%
Jul-25   13,47,544   2,70,102    10,77,442      9,08,366   67.4%
Aug-25   12,43,094   4,89,903     7,53,191      6,04,753   48.7%
Sep-25    7,96,105   6,93,200     1,02,905        -40,448   -5.1%
Oct-25    7,01,445   4,24,798     2,76,647         84,466   12.0%
Nov-25*   8,50,000   4,25,000     4,25,000      3,21,000   37.8%
Dec-25*   9,00,000   4,50,000     4,50,000      3,41,000   37.9%
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
TOTAL  1,11,45,272  55,58,720    55,86,552     30,94,223   27.8%

* Projected
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

---

## SLIDE 14: Balance Sheet (As of October 31, 2025)

### Projected Balance Sheet Statement

```
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
                    SKINSPIRE CLINIC
                  BALANCE SHEET (PROJECTED)
                  As of October 31, 2025
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

ASSETS                                           Amount (â‚¹)    %
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

CURRENT ASSETS
  Cash in Hand                                   14,78,189   13.3%
  Bank Balance                                    9,54,034    8.6%
  Medicine Inventory (Average)                   10,00,000    9.0%
  Accounts Receivable (Estimated)                 5,00,000    4.5%
                                              â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”€â”€â”€â”€â”€
TOTAL CURRENT ASSETS                             39,32,223   35.4%


FIXED ASSETS
  Capital Equipment (Net of Depreciation)        60,00,000   54.0%
  Furniture & Fixtures                            5,00,000    4.5%
  Medical Equipment                               6,79,391    6.1%
                                              â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”€â”€â”€â”€â”€
TOTAL FIXED ASSETS                               71,79,391   64.6%


TOTAL ASSETS                                   1,11,11,614  100.0%


â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

LIABILITIES & EQUITY                             Amount (â‚¹)    %
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

CURRENT LIABILITIES
  Accounts Payable                                3,00,000    2.7%
  Short-term Borrowings                          10,00,000    9.0%
  Accrued Expenses                                2,00,000    1.8%
                                              â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”€â”€â”€â”€â”€
TOTAL CURRENT LIABILITIES                        15,00,000   13.5%


LONG-TERM LIABILITIES
  Long-term Loan (Principal)                     20,00,000   18.0%
  Less: Repayments (10 months)                   -2,00,000   -1.8%
                                              â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”€â”€â”€â”€â”€
NET LONG-TERM LIABILITIES                        18,00,000   16.2%


TOTAL LIABILITIES                                33,00,000   29.7%


OWNER'S EQUITY
  Capital Contribution                           54,79,391   49.3%
  Retained Earnings (Beginning)                          -    0.0%
  Add: Net Profit (Jan-Oct 2025)                 24,32,223   21.9%
  Less: Personal Drawings                        -9,61,573   -8.7%
  Less: Capital Expenditure from Profit         -10,79,391   -9.7%
                                              â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”€â”€â”€â”€â”€
TOTAL OWNER'S EQUITY                             78,11,614   70.3%


TOTAL LIABILITIES & EQUITY                     1,11,11,614  100.0%


â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
                      FINANCIAL RATIOS
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Current Ratio                                2.62:1 (Healthy)
Debt-to-Equity Ratio                         0.42:1 (Conservative)
Return on Assets (10-month annualized)                    26.3%
Return on Equity (10-month annualized)                    37.4%
Inventory Turnover (Medicine)                          ~9.4 times
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

NOTES:
1. Medicine inventory maintained at average value of â‚¹10,00,000
2. Fixed assets include capital expenditure of â‚¹10.79L (Jan-Oct)
3. Long-term loan principal: â‚¹20L with monthly interest payments
4. Personal drawings represent owner's compensation
5. Balance sheet prepared on accrual basis
6. Estimated values marked with (Estimated)

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

---

## SLIDE 15: Key Performance Indicators (KPIs)

### Dashboard - Critical Business Metrics

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    OPERATIONAL KPIs                          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                              â”‚
â”‚  ğŸ“Š REVENUE METRICS                                          â”‚
â”‚  â”œâ”€ Average Monthly Revenue        : â‚¹9,39,527              â”‚
â”‚  â”œâ”€ Revenue Volatility (StdDev)    : 114% (High)            â”‚
â”‚  â”œâ”€ Peak Month Revenue             : â‚¹13,47,544 (July)      â”‚
â”‚  â”œâ”€ Lowest Month Revenue           : â‚¹6,29,780 (February)   â”‚
â”‚  â””â”€ Bank:Cash Ratio                : 76:24 (Healthy)        â”‚
â”‚                                                              â”‚
â”‚  ğŸ’° PROFITABILITY METRICS                                    â”‚
â”‚  â”œâ”€ Gross Profit Margin            : 50.15% âœ…              â”‚
â”‚  â”œâ”€ Net Profit Margin              : 25.89% âœ…              â”‚
â”‚  â”œâ”€ Average Monthly NP             : â‚¹2,43,222              â”‚
â”‚  â”œâ”€ Profitable Months              : 7/10 (70%)             â”‚
â”‚  â””â”€ Break-even Revenue             : â‚¹6.5L/month            â”‚
â”‚                                                              â”‚
â”‚  ğŸ“‰ EXPENSE METRICS                                          â”‚
â”‚  â”œâ”€ Operating Expense Ratio        : 49.85%                 â”‚
â”‚  â”œâ”€ Best OpEx Month                : July (20.1%)           â”‚
â”‚  â”œâ”€ Worst OpEx Month               : September (87.1%) âš ï¸   â”‚
â”‚  â”œâ”€ Personal Expense Ratio         : 10.23%                 â”‚
â”‚  â””â”€ CapEx as % of GP               : 27.97%                 â”‚
â”‚                                                              â”‚
â”‚  ğŸ’µ CASH FLOW METRICS                                        â”‚
â”‚  â”œâ”€ Operating Cash Flow            : â‚¹24,32,223             â”‚
â”‚  â”œâ”€ Free Cash Flow                 : â‚¹13,52,832             â”‚
â”‚  â”œâ”€ Cash Conversion Cycle          : ~30 days               â”‚
â”‚  â”œâ”€ Bank Cash Position             : â‚¹9,54,034              â”‚
â”‚  â””â”€ Cash in Hand Position          : â‚¹14,78,189             â”‚
â”‚                                                              â”‚
â”‚  ğŸ¯ EFFICIENCY METRICS                                       â”‚
â”‚  â”œâ”€ Revenue per Operating Rupee    : â‚¹2.01                  â”‚
â”‚  â”œâ”€ Return on Assets (annualized)  : 26.3%                  â”‚
â”‚  â”œâ”€ Return on Equity (annualized)  : 37.4%                  â”‚
â”‚  â”œâ”€ Current Ratio                  : 2.62:1 âœ…              â”‚
â”‚  â””â”€ Debt-to-Equity Ratio           : 0.42:1 âœ…              â”‚
â”‚                                                              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**PERFORMANCE SCORECARD:**

| Metric | Current | Target | Status | Priority |
|--------|---------|--------|--------|----------|
| **Revenue Stability** | 114% volatility | <20% | ğŸ”´ High | â­â­â­ |
| **Gross Margin** | 50.15% | >50% | âœ… Met | â­ |
| **Net Margin** | 25.89% | >25% | âœ… Met | â­ |
| **OpEx Ratio** | 49.85% | <45% | ğŸŸ¡ Close | â­â­ |
| **Monthly Profit** | 70% positive | 100% | ğŸŸ¡ Fair | â­â­ |
| **Cash Position** | â‚¹24.3L | Positive | âœ… Strong | â­ |

---

## SLIDE 16: Critical Issues & Action Required

### Top 3 Issues Requiring Immediate Attention

**ISSUE #1: REVENUE VOLATILITY & Q3 DECLINE** ğŸ”´ğŸ”´

**Problem:**
- Revenue swings: â‚¹6.3L to â‚¹13.5L (114% variance)
- Q3 decline: 25% drop from July peak
- September: 36% revenue decline

**Impact:**
- Unpredictable cash flow
- Difficulty in planning
- â‚¹6.5L monthly revenue loss from peak

**ROOT CAUSE ANALYSIS:**
```
Why revenue dropped?
â”œâ”€ Patient volume decline?
â”œâ”€ Seasonal factors?
â”œâ”€ Competition increase?
â”œâ”€ Service mix change?
â””â”€ Marketing effectiveness?
```

**ACTION PLAN (Immediate - 30 days):**
1. âœ… Conduct patient retention analysis
2. âœ… Implement monthly revenue tracking dashboard
3. âœ… Analyze July drivers (what worked?)
4. âœ… Review pricing strategy
5. âœ… Launch patient feedback survey
6. âœ… Develop Q4 marketing campaign

**Expected Outcome:**
- Stabilize revenue at â‚¹10L+/month
- Reduce volatility to <20%
- Improve predictability

---

**ISSUE #2: SEPTEMBER EXPENSE CRISIS** ğŸ”´ğŸ”´

**Problem:**
- Operating expenses: â‚¹6.93L on â‚¹7.96L revenue (87% ratio)
- Near-zero profitability (-â‚¹40K loss)
- Abnormal expense spike

**Impact:**
- Month-long loss
- Cash flow strain
- Profit erosion

**EXPENSE BREAKDOWN (September):**
```
What caused â‚¹6.93L OpEx?
â”œâ”€ Staff costs?          : â‚¹_____ (estimate needed)
â”œâ”€ Supplies/inventory?   : â‚¹_____ (estimate needed)
â”œâ”€ Utilities?            : â‚¹_____ (estimate needed)
â”œâ”€ Maintenance?          : â‚¹_____ (estimate needed)
â”œâ”€ One-time expenses?    : â‚¹_____ (estimate needed)
â””â”€ Other?                : â‚¹_____ (estimate needed)
```

**ACTION PLAN (Immediate - 15 days):**
1. ğŸ”´ URGENT: Conduct September expense audit
2. âœ… Identify one-time vs recurring costs
3. âœ… Implement monthly expense budgets by category
4. âœ… Review vendor contracts (top 5 suppliers)
5. âœ… Establish expense approval workflow (>â‚¹10K)
6. âœ… Set up weekly expense monitoring

**Expected Outcome:**
- Identify root cause
- Prevent recurrence
- Reduce OpEx to <50% of revenue

---

**ISSUE #3: BANK CASH FLOW VOLATILITY** ğŸ”´

**Problem:**
- Bank cash flow negative in 4/10 months (40%)
- September bank loss: -â‚¹3.4L (largest)
- Unpredictable bank position

**Impact:**
- Liquidity risk
- Potential overdraft
- Interest charges

**MONTHLY BANK FLOW:**
```
Negative Months:
â”œâ”€ February  : -â‚¹1.51L
â”œâ”€ May       : -â‚¹1.45L
â”œâ”€ September : -â‚¹3.40L (critical)
â””â”€ October   : -â‚¹1.17L

Positive Months:
â”œâ”€ July      : +â‚¹5.38L (exceptional)
â”œâ”€ April     : +â‚¹3.68L
â””â”€ March     : +â‚¹3.26L
```

**ACTION PLAN (30 days):**
1. âœ… Implement 13-week rolling cash forecast
2. âœ… Set minimum bank balance threshold (â‚¹5L)
3. âœ… Review payment collection efficiency
4. âœ… Analyze bank-to-cash conversion timing
5. âœ… Consider line of credit for smoothing
6. âœ… Weekly cash position review meetings

**Expected Outcome:**
- Positive bank flow every month
- Maintain â‚¹5L+ bank balance
- Improve cash visibility

---

## SLIDE 17: Strategic Recommendations

### 12-Month Action Roadmap

**PILLAR 1: REVENUE STABILIZATION & GROWTH**

**Goal:** â‚¹10L+ monthly revenue with <20% variance

**Tactics:**
1. **Patient Acquisition**
   - Launch referral program (existing patients)
   - Digital marketing campaign (â‚¹30K/month budget)
   - Community health camps (quarterly)
   - Corporate wellness partnerships

2. **Patient Retention**
   - Implement loyalty program
   - Post-treatment follow-up system
   - Patient satisfaction surveys
   - WhatsApp communication for appointments

3. **Revenue Mix Optimization**
   - Promote high-margin services
   - Expand aesthetic treatment offerings
   - Package deals for recurring treatments
   - Seasonal promotional campaigns

**Expected Impact:**
- Revenue increase: 15-20%
- Patient retention: 80%+
- Revenue volatility: <20%

---

**PILLAR 2: COST OPTIMIZATION**

**Goal:** Reduce operating expenses to <45% of revenue

**Tactics:**
1. **Expense Control**
   - Implement zero-based budgeting
   - Renegotiate top 10 vendor contracts
   - Review staff productivity & scheduling
   - Optimize inventory management (reduce wastage)

2. **Efficiency Improvements**
   - Automate appointment scheduling
   - Reduce paper-based processes
   - Energy efficiency audit
   - Bulk purchasing discounts

3. **Monthly Monitoring**
   - Category-wise expense budgets
   - Weekly expense review meetings
   - Variance analysis (actual vs budget)
   - Expense approval workflow (>â‚¹10K)

**Expected Impact:**
- Cost savings: â‚¹4-5L annually
- OpEx ratio: 45% (from 49.85%)
- Improved profitability: +5% margin

---

**PILLAR 3: CASH FLOW MANAGEMENT**

**Goal:** Positive cash flow every month, â‚¹5L+ bank balance

**Tactics:**
1. **Cash Forecasting**
   - 13-week rolling forecast (weekly update)
   - Daily cash position monitoring
   - Scenario planning (best/worst case)

2. **Collection Efficiency**
   - Same-day payment incentives (3% discount)
   - Digital payment promotion
   - Automated payment reminders
   - Reduce credit period (cash patients)

3. **Payment Planning**
   - Negotiate extended payment terms (suppliers)
   - Stagger large payments
   - Maintain â‚¹5L minimum bank balance
   - Emergency credit line (â‚¹10L facility)

**Expected Impact:**
- Zero negative bank flow months
- Improved liquidity
- Reduced finance charges

---

**PILLAR 4: FINANCIAL VISIBILITY & CONTROL**

**Goal:** Real-time financial dashboard, monthly business review

**Tactics:**
1. **Financial Dashboards**
   - Daily: Revenue, collections, cash position
   - Weekly: Expenses, patient volume, key metrics
   - Monthly: P&L, cash flow, balance sheet
   - Quarterly: Strategic review, budget vs actual

2. **Reporting & Analysis**
   - Monthly P&L by 5th of next month
   - Variance analysis (actual vs budget)
   - Trend analysis (YoY, MoM)
   - KPI scorecards

3. **Decision Support**
   - Service-wise profitability analysis
   - Patient cohort analysis
   - Break-even analysis by service
   - Investment ROI tracking

**Expected Impact:**
- Faster decision-making
- Early warning system for issues
- Data-driven strategy
- Improved accountability

---

## SLIDE 18: 90-Day Implementation Plan

### Detailed Quarterly Roadmap

**MONTH 1 (Days 1-30): STABILIZATION**

**Week 1-2:**
- [ ] âœ… Conduct September expense deep-dive audit
- [ ] âœ… Analyze July revenue drivers (what worked?)
- [ ] âœ… Implement weekly cash flow review meetings
- [ ] âœ… Set up daily revenue tracking dashboard
- [ ] âœ… Review all vendor contracts (identify top 10)

**Week 3-4:**
- [ ] âœ… Create monthly expense budgets by category
- [ ] âœ… Launch patient satisfaction survey
- [ ] âœ… Implement expense approval workflow (>â‚¹10K)
- [ ] âœ… Develop 13-week cash forecast model
- [ ] âœ… Set minimum bank balance policy (â‚¹5L)

**Deliverables:**
- âœ“ Expense audit report
- âœ“ Cash forecast model
- âœ“ Patient survey results
- âœ“ Expense budget templates

---

**MONTH 2 (Days 31-60): OPTIMIZATION**

**Week 5-6:**
- [ ] âœ… Launch patient retention program
- [ ] âœ… Renegotiate top 5 vendor contracts
- [ ] âœ… Implement digital payment incentives
- [ ] âœ… Review staff scheduling & productivity
- [ ] âœ… Set up monthly KPI dashboard

**Week 7-8:**
- [ ] âœ… Launch referral program for existing patients
- [ ] âœ… Optimize inventory management (reduce wastage)
- [ ] âœ… Implement service-wise profitability tracking
- [ ] âœ… Review pricing strategy (high-margin services)
- [ ] âœ… Conduct energy efficiency audit

**Deliverables:**
- âœ“ Patient retention program (live)
- âœ“ Vendor contract savings report
- âœ“ Monthly KPI dashboard
- âœ“ Service profitability analysis

---

**MONTH 3 (Days 61-90): GROWTH**

**Week 9-10:**
- [ ] âœ… Launch digital marketing campaign (â‚¹30K budget)
- [ ] âœ… Implement monthly business review process
- [ ] âœ… Launch seasonal promotional packages
- [ ] âœ… Review Q1 2026 budget vs actual
- [ ] âœ… Finalize Q1 2026 strategic plan

**Week 11-12:**
- [ ] âœ… Conduct quarterly business review
- [ ] âœ… Set FY 2026 financial targets
- [ ] âœ… Plan capacity expansion (if needed)
- [ ] âœ… Review all implemented changes (effectiveness)
- [ ] âœ… Prepare Q1 2026 action plan

**Deliverables:**
- âœ“ Q4 2025 performance report
- âœ“ FY 2026 budget & targets
- âœ“ 90-day implementation review
- âœ“ Q1 2026 action plan

---

**SUCCESS METRICS (90-Day Targets):**

| Metric | Current | 90-Day Target | Status |
|--------|---------|---------------|--------|
| Monthly Revenue | â‚¹9.4L avg | â‚¹10L+ | ğŸ¯ |
| Revenue Volatility | 114% | <30% | ğŸ¯ |
| OpEx Ratio | 49.85% | <47% | ğŸ¯ |
| Profitable Months | 70% | 90%+ | ğŸ¯ |
| Bank Balance | Variable | â‚¹5L+ always | ğŸ¯ |
| Customer Satisfaction | Unknown | 85%+ | ğŸ¯ |

---

## SLIDE 19: Expected Outcomes (12 Months)

### Projected Performance FY 2026

**IF RECOMMENDATIONS IMPLEMENTED:**

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚         PROJECTED FY 2026 PERFORMANCE                    â”‚
â”‚         (Jan 2026 - Dec 2026)                            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                          â”‚
â”‚  REVENUE                                                 â”‚
â”‚  â”œâ”€ Total Revenue         : â‚¹1.40 Cr                    â”‚
â”‚  â”œâ”€ Growth vs FY2025      : +25%                        â”‚
â”‚  â”œâ”€ Monthly Average       : â‚¹11.67L                     â”‚
â”‚  â””â”€ Volatility            : <20% (from 114%)            â”‚
â”‚                                                          â”‚
â”‚  PROFITABILITY                                           â”‚
â”‚  â”œâ”€ Gross Profit Margin   : 52% (from 50%)              â”‚
â”‚  â”œâ”€ Operating Expense %   : 43% (from 50%)              â”‚
â”‚  â”œâ”€ Net Profit Margin     : 35% (from 28%)              â”‚
â”‚  â””â”€ Total Net Profit      : â‚¹49L (from â‚¹31L)            â”‚
â”‚                                                          â”‚
â”‚  CASH FLOW                                               â”‚
â”‚  â”œâ”€ Operating Cash Flow   : â‚¹49L+                       â”‚
â”‚  â”œâ”€ Free Cash Flow        : â‚¹40L+ (after CapEx)         â”‚
â”‚  â”œâ”€ Minimum Bank Balance  : â‚¹8L+                        â”‚
â”‚  â””â”€ Negative Flow Months  : 0 (from 4)                  â”‚
â”‚                                                          â”‚
â”‚  EFFICIENCY                                              â”‚
â”‚  â”œâ”€ Cost Savings          : â‚¹8-10L annually             â”‚
â”‚  â”œâ”€ Patient Retention     : 85%+ (from ~70%)            â”‚
â”‚  â”œâ”€ Collection Efficiency : 95%+ (from ~85%)            â”‚
â”‚  â””â”€ Revenue/Employee      : +20%                        â”‚
â”‚                                                          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**COMPARATIVE ANALYSIS:**

| Metric | FY 2025 (Actual) | FY 2026 (Projected) | Change |
|--------|-----------------|---------------------|--------|
| **Revenue** | â‚¹1.11 Cr | â‚¹1.40 Cr | +â‚¹29L (+25%) |
| **Gross Profit** | â‚¹55.9L | â‚¹72.8L | +â‚¹16.9L (+30%) |
| **Net Profit** | â‚¹30.9L | â‚¹49.0L | +â‚¹18.1L (+59%) |
| **GP Margin** | 50.1% | 52.0% | +1.9% |
| **NP Margin** | 27.8% | 35.0% | +7.2% |
| **Monthly Avg Revenue** | â‚¹9.29L | â‚¹11.67L | +â‚¹2.38L (+26%) |
| **OpEx Ratio** | 49.9% | 43.0% | -6.9% |
| **Loss Months** | 3/12 | 0/12 | 100% improvement |

**GROWTH DRIVERS:**
1. **Revenue Growth (+25%)**
   - Patient volume: +15%
   - Average transaction value: +10%
   - Service mix optimization: +5%

2. **Margin Improvement (+7.2%)**
   - Cost optimization: +4%
   - Operating efficiency: +2%
   - Revenue mix: +1.2%

3. **Cash Flow Improvement**
   - Elimination of negative months
   - Improved collections (+10%)
   - Better payment terms

---

## SLIDE 20: Investment Opportunities

### Growth Investment Recommendations

**OPTION 1: EXPAND SERVICE OFFERINGS** ğŸ’° Low Investment

**Investment Required:** â‚¹5-8 Lakhs
**Payback Period:** 6-8 months
**ROI:** 60-80% annually

**Opportunities:**
- Advanced aesthetic treatments
- Laser therapy equipment
- Hair restoration services
- Anti-aging treatments

**Financial Impact:**
- Additional revenue: â‚¹2-3L/month
- Gross margin: 60%+
- Low operating costs

---

**OPTION 2: DIGITAL MARKETING & PATIENT ACQUISITION** ğŸ’°ğŸ’° Medium Investment

**Investment Required:** â‚¹3-5 Lakhs (annual budget)
**Payback Period:** 4-6 months
**ROI:** 100-150% annually

**Initiatives:**
- Google Ads & SEO (â‚¹30K/month)
- Social media marketing (â‚¹20K/month)
- Content marketing (â‚¹15K/month)
- Referral program incentives (â‚¹10K/month)

**Financial Impact:**
- New patient acquisition: +30%
- Revenue growth: +â‚¹3-4L/month
- Brand visibility: Significant improvement

---

**OPTION 3: OPERATIONAL EFFICIENCY UPGRADES** ğŸ’° Low Investment

**Investment Required:** â‚¹2-3 Lakhs
**Payback Period:** 3-4 months
**ROI:** 120%+ annually

**Upgrades:**
- Practice management software (â‚¹1L)
- Digital appointment system (â‚¹50K)
- Inventory management system (â‚¹30K)
- Patient communication automation (â‚¹20K)

**Financial Impact:**
- Staff productivity: +25%
- Operating cost reduction: â‚¹3-4L/year
- Patient satisfaction: +20%
- Inventory wastage: -30%

---

**RECOMMENDED PRIORITY:**

1. **Phase 1 (Q1 2026)**: Digital Marketing + Efficiency Upgrades
   - Total Investment: â‚¹5-8L
   - Quick wins, high ROI

2. **Phase 2 (Q2 2026)**: Expand Services (based on Q1 results)
   - Total Investment: â‚¹5-8L
   - Sustainable growth

3. **Phase 3 (Q3-Q4 2026)**: Capacity expansion (if needed)
   - Based on demand analysis

---

## SLIDE 21: Risk Analysis & Mitigation

### Top Business Risks & Mitigation Strategies

**RISK #1: CONTINUED REVENUE VOLATILITY** ğŸ”´

**Probability:** High (70%)
**Impact:** High (â‚¹5-10L/month swing)

**Mitigation Strategies:**
1. Diversify service offerings (reduce dependency)
2. Build recurring revenue streams (memberships)
3. Implement patient retention programs
4. Develop corporate partnerships (stable revenue)
5. Seasonal planning & promotions

**Monitoring:**
- Weekly revenue tracking
- Monthly variance analysis
- Patient volume trends

---

**RISK #2: EXPENSE CONTROL FAILURE** ğŸŸ¡

**Probability:** Medium (50%)
**Impact:** High (â‚¹3-5L/month excess costs)

**Mitigation Strategies:**
1. Monthly expense budgets by category
2. Approval workflow for expenses >â‚¹10K
3. Regular vendor contract reviews
4. Zero-based budgeting approach
5. Weekly expense review meetings

**Monitoring:**
- Daily expense tracking
- Weekly budget vs actual
- Monthly OpEx ratio

---

**RISK #3: CASH FLOW CRISIS** ğŸŸ¡

**Probability:** Medium (40%)
**Impact:** Very High (operational disruption)

**Mitigation Strategies:**
1. Maintain â‚¹5L minimum bank balance
2. 13-week rolling cash forecast
3. Emergency credit line (â‚¹10L)
4. Improve collection efficiency
5. Negotiate payment terms with suppliers

**Monitoring:**
- Daily cash position
- Weekly cash forecast update
- Monthly liquidity analysis

---

**RISK #4: COMPETITIVE PRESSURE** ğŸŸ¡

**Probability:** Medium (60%)
**Impact:** Medium (â‚¹2-3L/month revenue loss)

**Mitigation Strategies:**
1. Differentiate through service quality
2. Build strong patient relationships
3. Competitive pricing analysis
4. Continuous skill upgrades
5. Focus on niche specializations

**Monitoring:**
- Patient feedback scores
- Market share analysis
- Competitive benchmarking

---

**RISK #5: REGULATORY/COMPLIANCE** ğŸŸ¢

**Probability:** Low (20%)
**Impact:** High (â‚¹5-10L penalties/changes)

**Mitigation Strategies:**
1. Regular compliance audits
2. Stay updated on healthcare regulations
3. Maintain proper documentation
4. Professional indemnity insurance
5. Legal counsel on retainer

**Monitoring:**
- Quarterly compliance review
- Documentation audits
- License renewal tracking

---

## SLIDE 22: Key Takeaways & Next Steps

### Summary for CEO

**CURRENT STATE (Jan-Oct 2025):**

âœ… **What's Working:**
- 50% Gross Profit Margin (Healthy)
- 76% Bank Collections (Good audit trail)
- â‚¹24.3L Net Profit in 10 months (Positive)
- 70% Profitable months
- Strong cash generation

âš ï¸ **What Needs Attention:**
- 114% Revenue volatility (Very high)
- 3 Loss-making months (Feb, May, Sep)
- September expense crisis (87% OpEx)
- 4 months with negative bank flow
- Unpredictable monthly performance

---

**PROJECTED STATE (Full Year 2025):**

- **Revenue**: â‚¹1.11 Crores (Monthly Avg: â‚¹9.29L)
- **Net Profit**: â‚¹30.94 Lakhs (27.8% margin)
- **Gross Margin**: 50.1% (Stable)
- **Status**: 9 Profitable / 3 Loss months

---

**12-MONTH OUTLOOK (FY 2026 - IF ACTIONS TAKEN):**

ğŸ¯ **Targets:**
- Revenue: â‚¹1.40 Cr (+25% growth)
- Net Profit: â‚¹49L (+59% growth)
- Gross Margin: 52%
- Net Margin: 35%
- ALL 12 months profitable
- Zero negative bank flow months

---

**TOP 3 PRIORITIES (Next 90 Days):**

1. **ğŸ”´ URGENT: Stabilize Revenue**
   - Target: â‚¹10L+ monthly with <20% variance
   - Actions: Marketing campaign, patient retention, pricing review
   - Owner: CEO/Marketing Head
   - Timeline: 30 days to launch, 90 days to see impact

2. **ğŸ”´ URGENT: Control Operating Expenses**
   - Target: Reduce OpEx to <45% of revenue
   - Actions: Expense audit, vendor renegotiation, budgets
   - Owner: CFO/Operations Head
   - Timeline: 15 days audit, 45 days implementation

3. **ğŸŸ¡ HIGH: Improve Cash Flow Visibility**
   - Target: â‚¹5L+ bank balance always, zero negative months
   - Actions: Cash forecasting, collection efficiency, payment terms
   - Owner: Finance Manager
   - Timeline: 30 days to implement, ongoing monitoring

---

**IMMEDIATE NEXT STEPS (This Week):**

| Action | Owner | Deadline | Priority |
|--------|-------|----------|----------|
| Schedule 90-day planning session | CEO | 2 days | â­â­â­ |
| Initiate September expense audit | Finance | 3 days | â­â­â­ |
| Review July revenue drivers | Marketing | 3 days | â­â­â­ |
| Set up weekly cash review meeting | CFO | 5 days | â­â­ |
| Launch patient satisfaction survey | Operations | 5 days | â­â­ |
| Implement daily revenue dashboard | IT/Finance | 7 days | â­â­ |

---

**SUCCESS METRICS (12 Months):**

```
GOAL                          CURRENT    TARGET     STATUS
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Monthly Revenue                â‚¹9.3L     â‚¹11.7L      ğŸ¯
Revenue Stability              114%      <20%        ğŸ¯
Gross Profit %                 50%       52%         ğŸ¯
Net Profit %                   28%       35%         ğŸ¯
Operating Expense %            50%       43%         ğŸ¯
Profitable Months              9/12      12/12       ğŸ¯
Cash Flow Positive             70%       100%        ğŸ¯
Patient Satisfaction           TBD       85%+        ğŸ¯
```

---

**FINANCIAL PERFORMANCE RATING:**

**Current (FY 2025): B+**
- Strong fundamentals
- Good profitability
- High volatility concerns

**Projected (FY 2026): A-**
- With action plan implementation
- Stable & profitable operations
- Sustainable growth trajectory

---

## SLIDE 23: Questions & Discussion

### Open Floor for CEO & Management Team

**Discussion Points:**

1. **September Expense Crisis**
   - What caused the â‚¹6.93L operating expense spike?
   - Any one-time items we should be aware of?
   - Preventive measures needed?

2. **July Revenue Peak**
   - What drove the â‚¹13.5L revenue (39% jump)?
   - Can we replicate this performance?
   - Any learnings to systematize?

3. **Investment Decisions**
   - Priority: Marketing vs Equipment vs Systems?
   - Budget approval for 90-day plan?
   - Expected ROI timeline?

4. **Resource Requirements**
   - Need for additional staff?
   - Finance/accounting support?
   - External consultants?

5. **Strategic Direction**
   - Focus on growth vs profitability?
   - Service expansion priorities?
   - Geographic expansion plans?

---

**Contact for Follow-up:**

Financial Analysis Team
Skinspire Clinic
Email: finance@skinspire.com
Date: January 2025

---

**APPENDIX AVAILABLE:**
- Detailed monthly financial statements
- Variance analysis (budget vs actual)
- Service-wise profitability breakdown
- Patient cohort analysis
- Vendor contract review summary
- Cash flow forecasts (13-week rolling)

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
                         END OF PRESENTATION
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
